biotech / news / / KFF Health News
President Donald Trump bought as much as $680,000 in stock of Eli Lilly, the maker of blockbuster obesity drugs.
Donald Trump bought up to $680,000 of Eli Lilly stock as his administration advanced policies favoring the company.
KEY POINTS
- Several Trump stock purchases coincided with a new Medicare pilot offering GLP-1 drugs like Lilly's at $50 per month.
- White House initiatives steered Medicare reimbursement and FDA approvals benefiting Lilly's GLP-1 obesity drug business.
- Four of Trump's Lilly stock trades are listed as 'unsolicited,' but the disclosure's meaning is unclear.
- Lilly's market growth projections rely heavily on Medicare coverage for obesity drugs starting July 2026.
COMPANIES
Summarized by Newsio from KFF Health News. How we summarize →